Resistance management of Nivolumab

Nivolumab (Nivolumab) is an anti-tumor agent and a fully human anti-programmed death receptor-1 (anti-PD-1) monoclonal antibody. Nivolumab blocks PD-1 inhibitory signals from T cells and is administered every 2-4 weeks, so its effect is long-lasting. If patients require medication, physicians should inform patients of the risk of immune-mediated side effects, infusion-related side effects, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity.

Pharmacokinetic studies have shown that nivolumab exhibits linear pharmacokinetics, with peak concentration andAUC increasing proportionally to the dose. The time to reach peak plasma concentrations ranges from 1 to 4 hours. Resistance may be caused by a variety of factors, including tumor characteristics, immune system changes, etc. Since each person's resistance mechanism is different, if resistance occurs while taking nivolumab, you should consult a professional doctor to obtain the most appropriate advice and treatment plan. The doctor will confirm the resistance by conducting further examinations and evaluations, and evaluate your tumor status and overall health. Depending on the specific situation, the doctor may recommend switching to other immunotherapy or other types of treatment, such as chemotherapy, targeted therapy, or radiotherapy.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.